Antifungal agents for the treatment of systemic fungal infections in children
Antifungal agents for the treatment of systemic fungal infections in children
复制标题
DOI：
10.1155/2010/784549
复制
发表时间：
2010-12-01
影响因子：
2.8
通讯作者：
Allen, U. D.
中科院分区：
文献类型：
--
作者：
Allen, U. D.
传统上，全身抗真菌治疗的主要药物是去氧胆酸阿替霉素B（常规阿替霉素B）。已经开发了较新的药物，以满足特殊的小生境，并凭借更有利的毒性特征与传统的阿替霉素B竞争。一些药物已取代传统的阿替霉素B用于治疗特定的真菌疾病。例如，伏立康唑已成为侵袭性肺曲霉病的首选治疗方法。尽管如此，常规的阿替霉素B仍然是治疗儿科真菌感染的有用药物。鉴于接受这些药物治疗的患者数量不断增加，了解新药物的特性非常重要。在缺乏儿科数据的情况下，需要努力开展旨在生成这些数据的研究。本文所述的抗真菌剂最常用作单药治疗方案，因为除了特定情况外，对联合治疗的价值没有统一的共识。
Traditionally, the mainstay of systemic antifungal therapy has been amphotericin B deoxycholate (conventional amphotericin B). Newer agents have been developed to fulfill special niches and to compete with conventional amphotericin B by virtue of having more favourable toxicity profiles. Some agents have displaced conventional amphotericin B for the treatment of specific fungal diseases. For example, voriconazole has emerged as the preferred treatment for invasive pulmonary aspergillosis. This notwithstanding, conventional amphotericin B remains a useful agent for the treatment of paediatric fungal infections. Knowledge of the characteristics of the newer agents is important, given the increasing numbers of patients who are being treated with these drugs. Efforts need to be directed at research aimed at generating paediatric data where these are lacking. The antifungal agents herein described are most often used as monotherapy regimens because there is no uniform consensus on the value of combination therapy, except for specific scenarios.